SCHEMBL710204

SCHEMBL710204

FC(F)(F)Oc1cccc(CNCC2C3CN(Cc4ccccc4OC(F)(F)F)CC23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.45
CARM1 Q86X55 3/20 0.45
PRMT6 Q96LA8 3/20 0.45
CYP2D6 P10635 2/20 0.43
KCNH2 Q12809 2/20 0.43
CYP2C19 P33261 1/20 0.43
FFAR1 O14842 1/20 0.42
DRD4 P21917 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CTSD P07339 1/20 0.39
BACE1 P56817 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
OPRM1 P35372 1/20 0.38
CHRM4 P08173 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
MAPK14 Q16539 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15967210 0.90 CARM1 (0.45) CXCR4CARM1PRMT6KCNH2DRD4
SCHEMBL5510247 0.89 CARM1 (0.46) CXCR4CARM1PRMT6KCNH2DRD4
SCHEMBL708522 0.88 CARM1 (0.50) CARM1PRMT6KCNH2DRD4CTSD
SCHEMBL5517990 0.88 CARM1 (0.43) CXCR4CARM1PRMT6KCNH2DRD4
SCHEMBL5510263 0.87 CARM1 (0.44) CXCR4CARM1PRMT6KCNH2DRD4
SCHEMBL5510541 0.86 CARM1 (0.43) CARM1PRMT6KCNH2DRD4CTSD
SCHEMBL5511421 0.86 CARM1 (0.43) CXCR4CARM1PRMT6KCNH2DRD4
SCHEMBL5514659 0.86 CARM1 (0.46) CARM1PRMT6KCNH2DRD4CTSD
SCHEMBL712568 0.85 BACE1 (0.48) CARM1PRMT6KCNH2DRD4CTSD
SCHEMBL5511194 0.84 MAPK14 (0.49) CARM1PRMT6DRD4CTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 CXCR4 815/4885CARM1 2561/4885PRMT6 1238/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 CXCR4 890/4885CARM1 2205/4885PRMT6 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.